A Relaxation Response Resiliency Program (3RP) to Promote Stress Management and Resilience in Patients with Von Hippel-Lindau Disease

This clinical trial tests how well a relaxation response resiliency program (3RP) works in promoting stress management and resilience in patients with Von Hippel-Lindau disease (VHL). VHL is rare, inherited disorder that causes tumors and cysts to grow in certain parts of the body, including the brain, spinal cord, eyes, inner ear, adrenal glands, pancreas, kidney, and reproductive tract. The tumors are usually benign (not cancer), but some may be malignant (cancer). VHL patients experience a range of unique physical health challenges and have been identified as having unmet psychosocial needs (including symptoms such as chronic fatigue, anxiety, depression, high risk of recurrence, and fear of recurrence) persisting throughout the lifetime. The goal of the 3RP-VHL is to help reduce stress and promote stress-management among individuals diagnosed with VHL. Researchers want to learn if adapting a mind-body group program could help adults manage the challenges of living with a VHL diagnosis to reduce stress and improve the well-being and quality of life of patients living with VHL.

Additional locations may be listed on ClinicalTrials.gov for NCT05737602.

Trial PhaseNo phase specified

Trial Typesupportive care

Lead OrganizationDana-Farber Harvard Cancer Center

Principal InvestigatorGiselle Perez

• Primary ID22-612
• Secondary IDsNCI-2023-03075
• ClinicalTrials.gov IDNCT05737602